Colonoscopic Cancer Surveillance in Inflammatory Bowel Disease: What's New Beyond Random Biopsy?

James E. East

doi:10.5946/ce.2012.45.3.274

Articles

Page Path: HOME > Clin Endosc > Volume 45(3); 2012 > Article

Special Issue Articles of IDEN 2012 Session II - Lower Gut Colonoscopic Cancer Surveillance in Inflammatory Bowel Disease: What's New Beyond Random Biopsy?: James E. East; Clinical Endoscopy 2012;45(3):274-277.
DOI: https://doi.org/10.5946/ce.2012.45.3.274
Published online: August 22, 2012

Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.

Correspondence: James E. East. Translational Gastroenterology Unit, Experimental Medicine Division, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, University of Oxford, Headley Way, Headington, Oxford OX3 9DU, UK. Tel: +44-186-522-8753, Fax: +44-186-522-8763, jameseast6@yahoo.com

• Received: June 15, 2012 • Revised: July 26, 2012 • Accepted: July 27, 2012

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

6,991 Views
43 Download
21 Crossref
28 Scopus

prev next

Full Article

Download PDF

Abstract
INTRODUCTION
WHEN TO PERFORM SURVEILLANCE
BETTER WHITE LIGHT ENDOSCOPY
NEW TECHNOLOGY AND TECHNIQUES
CONCLUSIONS
NOTES
REFERENCES

Abstract

Colonoscopy based colitis surveillance is widely accepted to try to prevent development of and ensure early detection of colitis-associated colorectal cancer. Traditionally this has been performed with quadrantic random biopsies throughout the colon. Chromoendoscopy "dye-spray" with targeted biopsies only has been shown to increase dysplasia detection 4 to 5 fold on a per lesion basis. It has therefore been suggested that random biopsies should be abandoned as they do not increase dysplasia detection nor change patient clinical course. Recent British guidelines for colitis surveillance have strongly endorsed chromoendoscopy. This short review summarizes current international guidelines and looks at how to optimize white light colonoscopy in colitis considering: bowel preparation, withdrawal time, high definition, and structure enhancement. Data for advanced imaging techniques are reviewed including positive evidence in favor of chromoendoscopy, and limited data suggesting autofluoresence imaging may be promising. Narrow band imaging does not increase dysplasia detection in colitis. Confocal endomicroscopy might potentially reduce biopsies beyond that of chromoendoscopy but does not offer a clear detection advantage. Pan-colonic chromoendoscopy with targeted biopsies increases dysplasia detection and is the standard of care in the United Kingdom. It is likely that the use of chromoendoscopy for colitis surveillance will become widely accepted internationally.
Keywords: Ulcerative colitis; Crohn disease; Colonoscopy; Dysplasia; Surveillance

INTRODUCTION

Random biopsy, specifically quadrantic random biopsies taken every 10 cm throughout the colon during colonoscope withdrawal, has been a mainstay of colonoscopic inflammatory bowel disease (IBD) surveillance for the last 30 years. This arose from the premise that invisible so called "flat dysplasia in IBD" existed and was only detectable through histopathology. Random biopsy only samples 0.03% of the mucosal surface, has a detection rate of <2 per 1,000 biopsies and does not affect clinical decision making when advanced techniques are used.1,2 Although perhaps appropriate for its time when colonoscope optics were poorer (fibre optic or early video endoscopes) and colonoscopists were less familiar with the appearances of dysplasia in IBD, modern high definition (HD) instruments and adjunctive techniques make this now illogical as most dysplasia is or can be made visible. We have moved beyond random biopsy towards chromoendoscopy supported targeted biopsies only with endoscopic resection of circumscribed lesions. These two paradigm shifts in approach were recently specifically endorsed in the British Society of Gastroenterology (BSG) Guidelines 2010 for IBD surveillance3 as well as by the United Kingdom's National Institute for Clinical Excellence (NICE) Guidance 2011 (http://www.nice.org.uk/nicemedia/live/11877/48912/48912.pdf). NICE concluded that colonoscopic surveillance in IBD was cost effective for high risk groups, with an incremental cost effectiveness ratio (cost per quality adjusted life year) of £17,500 (US $27,150; ₩31,712,000). Nevertheless not all international guidelines have so far endorsed chromoendoscopy, summarized in Table 1.

WHEN TO PERFORM SURVEILLANCE

Colitis associated cancer risk increases with disease duration and disease extent. Surveillance is required for patients with both ulcerative colitis and Crohn's colitis as both are at increased risk. Previous British Guidelines recommended shorter surveillance intervals on the basis of disease duration as the risk was thought to increase exponentially to as much as 18% at 30 years;4 however more recent data from St. Mark's Hospital suggests risk may be linear and specific risk factors may be more important (Table 2). Risk in population based cohorts seems lower than from specialist centers. This has lead to the concept of risk stratified surveillance where those at highest risk e.g., with primary sclerosing cholangitis or previous dysplasia receive short surveillance intervals of 1 year, whist those at lowest risk e.g., left sided colitis without inflammation have longer surveillance intervals of 5 years. This risk based stratification is used in British Guidelines, and in part by European Crohn's and Colitis Organization (ECCO) guidance. The combination of risk based surveillance and chromoendoscopy without targeted biopsies may be cost saving.5

BETTER WHITE LIGHT ENDOSCOPY

Bowel preparation and clinical remission

We know that we need good bowel preparation to find polyps in non-colitic colonoscopy,6 and we also know that bowel preparation is worse in colitis, odds ratio 0.63 (95% confidence interval [CI], 0.40 to 0.98).7 The lack of research into bowel preparation in colitis is therefore puzzling, particularly for a patient group who need to have a good experience with bowel preparation for repeated examinations. Good quality prep in colitis is likely to improve detection rates, and is essential before trying to apply adjunctive techniques such as chromoendoscopy or other advanced imaging techniques. Similarly examination in clinical remission is critical to have a reasonable chance of detecting dysplasia, as detection of flat lesions against an inflamed background is much more difficult. Anecdotally patients not in remission also tend to prepare less well.

Withdrawal time

Taking longer for withdrawal has been clearly shown to be associated with improved adenoma detection in non-colitis patients. Logically this should also apply in colitis where detection is even more difficult. Toruner et al.8 were able to demonstrate this is a retrospective analysis looking at median procedure duration versus dysplasia detection rate and showed a significant association between longer procedure duration and increased dysplasia detection (R²=0.12; p=0.0066).

HD and structure enhancement (SE)

All major endoscope manufacturers offer HD instruments, with an option for push button digital image SE. This latter function helps improve edge definition, a critical element in detecting lesions in colitis. It is logical therefore to select the instrument with the best resolution and apply available SE to optimize white light endoscopy when performing colitis surveillance, though formal supportive data is lacking.

NEW TECHNOLOGY AND TECHNIQUES

Chromoendoscopy

There have been at least five of studies that have looked at the efficacy of chromoendoscopy for colitis surveillance utilizing randomized, back-to-back, and case-control designs (Table 3).9-13 All have been positive in favor of chromoendoscopy with a per patient increase in dysplasia of approximately 2 to 3 fold and a per lesion increase of 4 to 5 fold. Studies have used both methylene blue and indigo carmine. Given the consistent evidence in favor of chromoendoscopy BSG guidelines in 2010 strongly endorsed chromoendoscopy with targeted biopsies of circumscribed lesions but without random biopsies. ECCO Guidelines give more qualified support. Kiesslich and Neurath14 give a helpful summary of how to optimize chromoscopic technique in their SURFACE guidelines. Although more time consuming than white light endoscopy alone, an extra 10 to 15 minutes, the time is probably equivalent to white light examination with 32 or more biopsies.

Narrow band imaging (NBI) and autofluorescence

There was great hope that NBI would be able to act as a form of "electronic chromoendoscopy" to make colitis surveillance more efficient. Unfortunately, probably due to the background inflammation, dysplasia detection was no different to white light in two tandem studies and one multi-centre, randomized, parallel group study (Table 4).15-17 It seems unlikely that NBI will be helpful for dysplasia detection in colitis. Autofluorescence imaging (AFI) has had more success with a case report suggesting that 50% of AFI positive lesions were dysplastic. A small (n=50) back-to-back study showed a lower miss rate with AFI than white light (0/10 vs. 3/6, p=0.036).18 Anecdotally inflammation is a problem.

Confocal endomicroscopy

Confocal endomicroscopy has been proposed as an addition to chromoscopically detected lesions to help target biopsies and reduce their number. In a study by Kiesslich et al.,11 chromoendoscopy reduced biopsies 10-fold. Addition of confocal could have reduced the number of biopsies a further 5-fold to approximately 1 per patient.11 Although there is the potential to have to take very few biopsies, the technique is technically demanding and the instruments currently unwieldy and not HD. Given two expert pathologists are required to make a clear diagnosis of dysplasia in IBD, the challenge for a single endoscopist to do this in vivo is considerable. Definite advantages of this approach are not yet conclusively demonstrated.

CONCLUSIONS

Pan-colonic chromoendoscopy without random biopsies is now the standard of care in the United Kingdom for colonoscopic colitis surveillance and is likely to be adopted more widely. This will lead to increased dysplasia detection. Other technologies are not yet proven, though AFI has some promise. Strategies where endoscopically resected polypoid dysplasia in colitis leads to further surveillance rather then colectomy will need to be considered.

The author has no financial conflicts of interest.

REFERENCES

1. East JE, Saunders BP, Burling D, Boone D, Halligan S, Taylor SA. Surface visualization at CT colonography simulated colonoscopy: effect of varying field of view and retrograde view. Am J Gastroenterol 2007;102:2529–2535.Article PubMed
2. van den Broek FJ, Stokkers PC, Reitsma JB, et al. Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis: low yield and absence of clinical consequences. Am J Gastroenterol Epub 2011 Mar 22. DOI:http://dx.doi.org/10.1038/ajg.2011.93Article
3. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666–689.Article PubMed
4. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526–535.Article PubMed PMC
5. Elsadani NN, East JE, Walters JR. New 2010 British Society of Gastroenterology colitis surveillance guidelines: costs and surveillance intervals. Gut 2011;60:282–283.Article
6. Barclay RL, Vicari JJ, Doughty AS, Johanson JF, Greenlaw RL. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 2006;355:2533–2541.Article PubMed
7. Froehlich F, Wietlisbach V, Gonvers JJ, Burnand B, Vader JP. Impact of colonic cleansing on quality and diagnostic yield of colonoscopy: the European Panel of Appropriateness of Gastrointestinal Endoscopy European multicenter study. Gastrointest Endosc 2005;61:378–384.Article PubMed
8. Toruner M, Harewood GC, Loftus EV Jr, et al. Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease. Inflamm Bowel Dis 2005;11:428–434.Article PubMed
9. Hurlstone DP, Sanders DS, Lobo AJ, McAlindon ME, Cross SS. Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy 2005;37:1186–1192.Article PubMed
10. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003;124:880–888.Article PubMed
11. Kiesslich R, Goetz M, Lammersdorf K, et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 2007;132:874–882.Article PubMed
12. Marion JF, Waye JD, Present DH, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol 2008;103:2342–2349.Article PubMed
13. Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 2004;53:256–260.Article PubMed PMC
14. Kiesslich R, Neurath MF. Surveillance colonoscopy in ulcerative colitis: magnifying chromoendoscopy in the spotlight. Gut 2004;53:165–167.Article PubMed PMC
15. Dekker E, van den, Reitsma JB, et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy 2007;39:216–221.Article PubMed
16. van den Broek FJ, Fockens P, van Eeden S, et al. Narrow-band imaging versus high-definition endoscopy for the diagnosis of neoplasia in ulcerative colitis. Endoscopy 2011;43:108–115.Article PubMed
17. Ignjatovic A, East JE, Subramanian V, et al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. Am J Gastroenterol Epub 2012 May 22. DOI:http://dx.doi.org/10.1038/ajg.2012.67Article
18. van den Broek FJ, Fockens P, van Eeden S, et al. Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions. Gut 2008;57:1083–1089.Article PubMed PMC

Table 1

Comparison of Screening Recommendation from International Guidelines for Patients with Colitis

ECCO, European Crohn's and Colitis Organization; BSG, British Society of Gastroenterology; NICE, National Institute for Clinical Excellence; AGA, American Gastroenterological Association; ACG, American College of Gastroenterology; PSC, primary sclerosing cholangitis.

Table 2

Risk Factors for Dysplasia in Ulcerative Colitis

Table 3

Summary of Trials Comparing White Light and Chromoendoscopy Dysplasia Detection for Colitis Surveillance on a per Patient Basis

CI, confidence interval.

Table 4

Outcomes of Studies Comparing NBI and WLE for Dysplasia Detection in Colitis

NBI, narrow band imaging; WLE, white light endoscopy.

^a)Proportion of total dysplastic lesions detected overall; ^b)Proportion of patients with at least one dysplastic lesion.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Colon Cancer
Sherief Shawki, Jean Ashburn, Steven A. Signs, Emina Huang
Surgical Oncology Clinics of North America.2018; 27(2): 269. CrossRef
Advanced endoscopic imaging for diagnosis of inflammatory bowel diseases: Present and future perspectives
Visvakanth Sivanathan, Gian Eugenio Tontini, Markus Möhler, Peter R. Galle, Helmut Neumann
Digestive Endoscopy.2018; 30(4): 441. CrossRef
Chromoendoscopy for Dysplasia Surveillance in Inflammatory Bowel Disease
Ann D Flynn, John F Valentine
Inflammatory Bowel Diseases.2018; 24(7): 1440. CrossRef
Early detection of ulcerative colitis-associated colorectal cancer
Yu Zhen, Chengxin Luo, Hu Zhang
Gastroenterology Report.2018; 6(2): 83. CrossRef
Screening and surveillance methods for dysplasia in inflammatory bowel disease patients: Where do we stand?
Michail Galanopoulos, Emmanouela Tsoukali, Filippos Gkeros, Marina Vraka, Georgios Karampekos, Gerassimos J Matzaris
World Journal of Gastrointestinal Endoscopy.2018; 10(10): 250. CrossRef
The rectal remnant after total colectomy for colitis – intra-operative,post-operative and longer-term considerations
Kalle Landerholm, Christopher Wood, Alexander Bloemendaal, Nicolas Buchs, Bruce George, Richard Guy
Scandinavian Journal of Gastroenterology.2018; 53(12): 1443. CrossRef
Crohn's disease: risk factor for colorectal cancer
Sandra Cristina Dias dos Santos, Laura Elisabete Ribeiro Barbosa
Journal of Coloproctology.2017; 37(01): 055. CrossRef
Chromoendoscopy for Surveillance in Ulcerative Colitis and Crohn’s Disease: A Systematic Review of Randomized Trials
Andrea Iannone, Marinella Ruospo, Germaine Wong, Mariabeatrice Principi, Michele Barone, Giovanni F.M. Strippoli, Alfredo Di Leo
Clinical Gastroenterology and Hepatology.2017; 15(11): 1684. CrossRef
Chinese consensus on the prevention of colorectal cancer (2016, Shanghai)
Jing‐Yuan Fang, Yong Quan Shi, Ying Xuan Chen, Jing Nan Li, Jian Qiu Sheng
Journal of Digestive Diseases.2017; 18(2): 63. CrossRef
Advanced imaging and therapeutic endoscopy
Chaitanya Pant, Mojtaba S. Olyaee, Amit Rastogi
Techniques in Gastrointestinal Endoscopy.2017; 19(3): 151. CrossRef
Improving the utility of colonoscopy: Recent advances in practice
Crispin J Corte, Rupert W Leong
Journal of Gastroenterology and Hepatology.2016; 31(1): 32. CrossRef
Colorectal Cancer in Patients With Inflammatory Bowel Disease: The Need for a Real Surveillance Program
Rosario Fornaro, Michela Caratto, Elisa Caratto, Giuseppe Caristo, Francesco Fornaro, Davide Giovinazzo, Camilla Sticchi, Marco Casaccia, Enzo Andorno
Clinical Colorectal Cancer.2016; 15(3): 204. CrossRef
How to Optimize Colon Cancer Surveillance in Inflammatory Bowel Disease Patients
Jill K. J. Gaidos, Stephen J. Bickston
Inflammatory Bowel Diseases.2016; 22(5): 1219. CrossRef
Endoscopy in the Diagnosis and Management of Complications of Inflammatory Bowel Disease
Benjamin Tharian, Nayana George, Udayakumar Navaneethan
Inflammatory Bowel Diseases.2016; 22(5): 1184. CrossRef
Surveillance of patients with inflammatory bowel disease
Jessica X. Yu, James E. East, Tonya Kaltenbach
Best Practice & Research Clinical Gastroenterology.2016; 30(6): 949. CrossRef
The role of endoscopy in inflammatory bowel disease
Amandeep K. Shergill, Jenifer R. Lightdale, David H. Bruining, Ruben D. Acosta, Vinay Chandrasekhara, Krishnavel V. Chathadi, G. Anton Decker, Dayna S. Early, John A. Evans, Robert D. Fanelli, Deborah A. Fisher, Lisa Fonkalsrud, Kimberly Foley, Joo Ha Hwa
Gastrointestinal Endoscopy.2015; 81(5): 1101. CrossRef
Chromoendoscopy for Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Disease
Samir A. Shah, David T. Rubin, Francis A. Farraye
Current Gastroenterology Reports.2014;[Epub] CrossRef
Toward a Consensus on Endoscopic Surveillance of Patients with Colonic Inflammatory Bowel Disease
Amandeep K. Shergill, Francis A. Farraye
Gastrointestinal Endoscopy Clinics of North America.2014; 24(3): 469. CrossRef
Achieving the best bowel preparation for colonoscopy
Adolfo Parra-Blanco, Alex Ruiz, Manuel Alvarez-Lobos, Ana Amorós, Juan Cristóbal Gana, Patricio Ibáñez, Akiko Ono, Takahiro Fujii
World Journal of Gastroenterology.2014; 20(47): 17709. CrossRef
Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis
Eun Ran Kim
World Journal of Gastroenterology.2014; 20(29): 9872. CrossRef
Highlights of the 48th Seminar of Korean Society of Gastrointestinal Endoscopy
Kwang An Kwon, Il Ju Choi, Eun Young Kim, Seok Ho Dong, Ki Baik Hahm
Clinical Endoscopy.2013; 46(3): 203. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.